Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord blood-derived mononuclear cells (Shandong Qilu Stem Cell Engineering)
- Development stage
- Unknown
- Lead developer
- Shandong Qilu Stem Cell Engineering
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Umbilical cord blood-derived mononuclear cells (UCB-MNCs) is an investigational cell therapy developed by Shandong Qilu Stem Cells Engineering Co., Ltd. for the treatment of refractory neonatal conditions, including hypoxic-ischemic encephalopathy (HIE), bronchopulmonary dysplasia (BPD), and short bowel syndrome (SBS). The therapy consists of a heterogeneous population of mononuclear cells isolated from human umbilical cord blood via density gradient centrifugation, which includes hematopoietic stem cells, mesenchymal stem cells, and various progenitor cells. These cells are hypothesized to function through paracrine signaling, secreting a variety of growth factors and anti-inflammatory cytokines that promote angiogenesis, modulate the immune response, and stimulate endogenous tissue repair and regeneration. In clinical evaluation, the cells are typically administered via intravenous infusion to neonates to improve outcomes in serious diseases where standard treatments are often insufficient.
- Other names
- Umbilical cord blood-derived mononuclear cellsUCB-MNC
Beyond the preview
Go deeper on umbilical cord blood-derived mononuclear cells (Shandong Qilu Stem Cell Engineering).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord blood-derived mononuclear cells (Shandong Qilu Stem Cell Engineering).